(Q36449509)

14 August 2017

1 reference

title

New agents in chronic lymphocytic leukemia. (English)

1 reference

14 August 2017

0 references

1

Tadeusz Robak

1 reference

14 August 2017

publication date

1 May 2006

1 reference

Current Treatment Options in Oncology

14 August 2017

published in

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

200-212

1 reference

Oral fludarabine therapy in chronic lymphocytic leukemia--increased convenience

14 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11864-006-0013-X

Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia

21 January 2018

1 reference

12 December 2020

Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia

1 reference

12 December 2020

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

1 reference

12 December 2020

Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia

1 reference

12 December 2020

Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab

1 reference

12 December 2020

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia

1 reference

12 December 2020

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

12 December 2020

CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.

1 reference

12 December 2020

The role of stem cell transplantation in chronic lymphocytic leukemia

1 reference

12 December 2020

Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial

1 reference

12 December 2020

Chronic lymphocytic leukemia

1 reference

12 December 2020

The clinical and epidemiological burden of chronic lymphocytic leukaemia

1 reference

12 December 2020

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

1 reference

12 December 2020

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine

1 reference

12 December 2020

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

1 reference

12 December 2020

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

1 reference

12 December 2020

Novel immune-based treatment strategies for chronic lymphocytic leukemia

1 reference

12 December 2020

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

12 December 2020

Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia.

1 reference

12 December 2020

Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group

1 reference

12 December 2020

Classical and new prognostic factors in chronic lymphocytic leukemia: where to now?

1 reference

12 December 2020

Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications

1 reference

12 December 2020

Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia

1 reference

12 December 2020

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

1 reference

12 December 2020

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile

1 reference

12 December 2020

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

12 December 2020

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

1 reference

12 December 2020

Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia

1 reference

12 December 2020

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

1 reference

12 December 2020

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

1 reference

12 December 2020

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia

1 reference

12 December 2020

Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial.

1 reference

12 December 2020

CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia

1 reference

12 December 2020

Phase II study of alemtuzumab in chronic lymphoproliferative disorders

1 reference

12 December 2020

Chronic lymphocytic leukaemia: new biological markers for assessing prognosis.

1 reference

12 December 2020

ZAP-70 expression and prognosis in chronic lymphocytic leukaemia

1 reference

12 December 2020

Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia

1 reference

12 December 2020

Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia

1 reference

12 December 2020

ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

1 reference

12 December 2020

Rituximab dose-escalation trial in chronic lymphocytic leukemia

1 reference

12 December 2020

Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group

1 reference

12 December 2020

When and how to treat chronic lymphocytic leukemia

1 reference

12 December 2020

High dose chlorambucil in the treatment of lymphoid malignancies

1 reference

12 December 2020

Novel therapies for chronic lymphocytic leukemia

1 reference

12 December 2020

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL

1 reference

12 December 2020

Detection of minimal residual disease in B Chronic Lymphocytic Leukemia (CLL)

1 reference

12 December 2020

Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia

1 reference

12 December 2020

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

12 December 2020

Genomic aberrations and survival in chronic lymphocytic leukemia

1 reference

12 December 2020

10.1007/S11864-006-0013-X

Identifiers

DOI

1 reference

14 August 2017

1 reference